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Purpose: In the TROG 96.01 trial 6 month neo-adjuvant androgen suppression (NAS) and radiotherapy
(RT) for locally advanced prostate cancer prevented distant progressions (DPs) when compared to RT
alone, but 3 months did not. We ask why?
Methods: Between 1996 and 2000, 802 men with T2-4 N0 M0 prostate cancers received RT alone
(0 month NAS) to 66 Gy, 3 months or 6 months NAS before RT. Interval hazards and cumulative inci-
dences of DP were compared using competing risks methodology.
Results: In the ﬁrst 4 follow-up years 39, 40 and 26 DPs were diagnosed in subjects treated with 0, 3 and
6 month NAS, respectively. Compared with 0 month, signiﬁcant reductions in PSA doubling time in sub-
jects with DP occurred following 3 month NAS (p = 0.01), but a signiﬁcant reduction (p = 0.01) and a near
signiﬁcant delay in DPs (p = 0.06) occurred after 6 month NAS. Subsequently 25, 20 and 11 DPs occurred
in the three trial arms. After early secondary therapy for PSA or local progression 34, 19 and 12 DPs were
diagnosed after median delays of almost 4 years.
Conclusions: The data are consistent with the failure of 3 month NAS to prevent the progression of sub-
clinical metastatic deposits already present before treatment.
 2013 Elsevier Ireland Ltd. Radiotherapy and Oncology 107 (2013) 123–128 Open access under CC BY-NC-NDThe three arm TROG 96.01 trial for men with locally ad-
vanced prostate cancer produced a straightforward result. After
10 year minimum follow-up, distant metastatic progressions
(DPs) were reduced by half in the 6 month neo-adjuvant andro-
gen suppression (NAS) plus radiotherapy arm when compared
with the radiotherapy alone and 3 month NAS plus radiotherapy
arms.
Unfortunately only one other trial dataset has produced data
that have a bearing on this hypothesis. This was the RTOG
86.10 trial in men with locally advanced prostate cancer which
compared radiotherapy alone with the same radiotherapy com-
mencing 2 months after a 4 month course of AS. Four month AS
was found to reduce subsequent DPs by approximately 24% [1].ession; LP, local progression;
intervention (aka ‘‘salvage
ng time.
castle, Locked Bag 1, Hunter
. Denham).
nder CC BY-NC-ND license.A subset analysis revealed that the reduction in DPs was re-
stricted to men with Gleason score 66 tumours where the reduc-
tion was 62% [1].
At ﬁrst sight the TROG 96.01 trial result suggests that there is a
threshold duration of NAS, somewhere between 3 and 6 months,
above which a large proportion of sub-clinical metastatic deposits
present before treatment is eradicated. The RTOG 86.10 trial indi-
cates that this threshold is between 3 and 4 months in subjects
with low grade cancers.
A second look at the TROG 96.01 trial data suggests that while
this hypothesis may be correct, the inﬂuence of treatment on met-
astatic progression is more complex. When compared with the
radiotherapy only arm, the 3 month NAS arm reduced local (pros-
tatic) progression by 50% and the 6 month arm by 55%. Almost cer-
tainly these large reductions would have produced measurable
reductions in metastases that originated after treatment from the
uncontrolled primary tumour. Why, therefore, has 3 month NAS
produced no overall reduction in DPs compared to the radiother-
apy only arm? In this report we explore the reasons for this para-
doxical ﬁnding.
124 Metastatic processes in prostate cancerMethods
Subjects
Data for the present study came from the 802 eligible patients
who participated in the TROG 9601 trial, described in detail previ-
ously [2]. Between 1996 and 2000, men with T2b, T2c, T3 and T4
prostatic adenocarcinoma, after providing informed consent were
randomised to one of three treatment arms. In the control arm
radiotherapy (RT) alone to the prostate and seminal vesicles to a
dose of 66 Gy was delivered in daily fractions of 2 Gy. In the two
experimental arms neo-adjuvant androgen suppression therapy
(NAS) using monthly goserelin 36 mg (AstraZeneca Pty Ltd., Syd-
ney, Australia) subcutaneously and ﬂutamide 250 mg (Schering-
Plough Pty Ltd., Sydney, Australia) orally three times a day was
administered before and during RT. NAS began 2 months before
radiation in the 3 month NAS arm and 5 months before radiation
in the 6 month NAS arm.Follow-up, endpoints and quality control
Patients were followed up 2 months after radiotherapy, every
4 months for 2 years, and every 6 months thereafter for a further
3 years. If free of all signs of cancer patients were then followed
annually. At each follow-up visit digital rectal examination and
serum PSA estimation were performed.
Endpoints in the present study were PSA progression, local pro-
gression (LP) and DP. LP was deﬁned as occurring at the time of
ﬁrst progression of malignant induration or conﬁrmatory biopsy
or trans-urethral resection P2 years after treatment. DP was de-
ﬁned as metastasis at anatomical sites outside of the prostatic re-
gion. PSA progression was determined using the Phoenix method
(i.e. time from end of radiotherapy to a PSA rise of 2 ng/mL above
the post-treatment nadir). Time to all endpoints was measured
from randomisation. PSA doubling times (PSADTs) were estimated
using the value prior to Phoenix progression up until STI or last fol-
low-up. A spline ﬁtting procedure allowed signiﬁcant changes in
PSADT to be detected [3].
Site monitoring visits were performed to verify source data. All
relapse and mortality data were reviewed by a blinded Endpoints
Committee.Statistical methods
Cumulative incidence of competing risks methodology was
used to compare DP in the three trial arms. The Fine and Gray
method [4] was used to derive adjusted HRs and p-values for com-
parison of treatment arms. Adjusting factors were: age (<70 vs
P70), Gleason score (2–6 vs 7 vs 8–10), initial PSA (<20 vs
P20 lg/L), and stage (T2b vs T2c vs T3 and T4). Unless speciﬁed
otherwise competing risk events were STI and death due to any
cause. Life tables were used to derive 2 yearly interval hazards of
DP from randomisation to illustrate their respective time-courses
because the proportion of DPs was relatively small. Chi-square
tests were used to compare categorical data, and the Wilcoxon
rank-sum for continuous data.
A two-sided p-value <005 was considered signiﬁcant because
all analyses were exploratory. Stata Version 112 was used for all
analyses.Fig. 1. Hazard rates of distant progression before secondary therapeutic interven-
tion by treatment arm.Assumptions concerning the time-course of distant progression in
interpreting the data
Our ﬁrst assumption is that metastases originate from the pri-
mary, both prior to its treatment and after treatment if the primary
tumour remains viable. Metastases originating before treatmentare likely to be diagnosed at earlier timepoints after treatment
than metastases originating after treatment. In the electronic sup-
plement we discuss what is known of prostate cancer cellular
kinetics [5–9] and its relevance to the duration of the sub-clinical
growth phase of prostate cancer metastases, i.e. the time it takes
for a single clonogenic metastatic cell to be diagnosed as a small
metastasis. We then estimate that the shortest duration of this
phase would be between 1.1 and 2.7 years but would apply to only
the most rapidly growing cancers. The median duration, applying
to most tumours, would be 1.9–13.8 years, and longest duration,
associated with the most slowly growing tumours, would range
between 4.9 and 32.4 years. In clinical terms this means that the
great majority of DPs diagnosed in the ﬁrst four years of follow-
up in the present study will have originated from sub-clinical met-
astatic deposits present before treatment, though many will also
be diagnosed at later timepoints. Our second assumption is that
NAS could both have delayed and prevented the growth of sub-
clinical metastases, but that secondary therapy with AS following
PSA or local progression could have delayed but not prevented
DPs. Our third assumption is that lack of clinical evidence of LP
does not rule out the possibility that DPs can originate from uncon-
trolled primary tumours, because digital examinations underesti-
mate the presence of viable cancer in irradiated prostates. These
assumptions have enabled us to advance plausible explanations
for the proportion of DPs that originate from sub-clinical metasta-
ses and the proportion of metastases ‘‘induced’’ by local
progression.Results
Of the 802 eligible men, 519 had experienced progression by
data close-out on 31 August 2010. Of these, 244 (47.0%) had PSA
progressions without evidence of clinical progression; 275
(53.0%) had clinical progression diagnosed before secondary thera-
peutic intervention (STI); 114 occurred in the prostate alone (‘‘LP
only’’), and 109 at metastatic sites alone (‘‘DP only’’). A smaller
group of subjects had evidence of local and DPs (‘‘LP/DP’’, n = 52).
In the majority of these subjects (n = 46) DP was diagnosed at
the time of LP or afterwards. STI was commenced in 88 subjects
experiencing LP only before DP could be diagnosed. Ultimately
DP was diagnosed after STI in 31 of these subjects. STI was also
commenced in 123 subjects with PSA progression without CP. In
34 of these subjects DP was diagnosed after STI.Time-course of diagnosed distant progressions
The time-course of the hazards of DPs occurring before STI is
presented by treatment arm in Fig. 1. During the ﬁrst two years
Number of events* 
 RT alone 10 13 6 10 6 6 0 1 
 3 month NAS  3 19 7 11 7 2 4 1 
 6 month NAS  1 9 5 11 1 7 1 1 
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Fig. 2. Cumulative incidence of distant progression occurring in the ﬁrst 7.5 years of follow-up by treatment arm. Abbreviations: RT, radiotherapy; NAS, neo-adjuvant
androgen suppression therapy. ⁄Number of distant progression diagnosed before secondary therapeutic intervention.
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progression of sub-clinical metastases present at the time of treat-
ment, similar numbers of subjects in the 3 month NAS arm (n = 22),
and in the control (RT alone) arm (n = 23) had DPs, but the number
of subjects in the 6 month NAS arm was considerably smaller
(n = 10). The cumulative incidence of DP plots in Fig. 2 indicate that
DP diagnosis occurred at a more rapid rate in the 3 month NAS
arm, particularly in the second year of follow-up. This observation
led us to compare the PSADT of subjects experiencing DPs in the
ﬁrst 7.5 years of follow up i.e. when a large proportion of DPs
would have arisen from sub-clinical metastases (see electronic
supplement). This was to ﬁnd out whether testosterone recovery
following NAS could have accelerated metastatic tumour progres-
sion, particularly in subjects receiving 3 month NAS. Table 1 indi-
cates that PSA doubling time (PSADT) was more rapid in the
3 month NAS arm (p = 0.01) and that this phenomenon was most
common in DPs occurring in the ﬁrst ﬁve follow-up years. These
ﬁndings are explored in the electronic supplement (Figs. S1 and
S2). Fig. S1 presents the absolute frequencies of PSADT in subjects
developing DPs in their ﬁrst 7.5 years of follow-up; it shows that
the number of subjects receiving 3 month NAS with PSADTs
63 months was markedly increased compared to those receiving
RT alone (p = 0.01). Fig. S2 presents the relative frequencies of
PSADTs and conﬁrms the relative increase in rapid PSADTs in sub-
jects receiving 3 month NAS. However it also suggests a relative in-
crease in rapid PSADTs in subjects treated with 6 month NAS.
While this could mean that PSADTs were shortened in the 6 month
NAS arm, it could also mean that 6 month NAS eradicated substan-
tial numbers of sub-clinical metastases present at diagnosis associ-
ated with PSADTs >3 months. Whether these rapid PSADT failures
increased the rapidity of metastatic progression, however, is un-
clear. This is because the data in Table 1 and Figs. 1 and 2 suggest
that the timing of DPs in the two NAS arms is more compatible
with delays in the DP process rather than accelerations. When
compared with the RT alone arm, the DP timing data in the
6 month arm are compatible with a delay in the diagnosis of some
metastatic progressions (p = 0.06), particularly from follow-up
years 1–2 until years 3–4, and the prevention of progression in alarge number of others (Grays p < 0.01). However in the 3 month
NAS arm where the prevention of metastatic progressions did
not occur, delays in progression were shorter. Fig. 2 suggests that
DPs which were likely to have occurred in the ﬁrst follow-up year
in subjects receiving 3 month NAS instead occurred in the second.
For these reasons the number of DPs diagnosed in the third and
fourth years, which most likely arose from sub-clinical metastases
present before treatment (see electronic supplement), was similar
in the three trial arms. The PSADT data presented in Table 1 indi-
cate that PSADTs in subjects experiencing progressions in both
NAS treatment arms were still more rapid than in progressing sub-
jects receiving RT alone. However, as pointed out above, this does
not necessarily indicate an induced shortening of PSADT occurred
in subjects on the 6 month NAS arm.
In follow-up years 5.0–7.5 when some of the DPs could have
originated from uncontrolled primary tumours (i.e. LP induced
metastases [see electronic supplement]), DPs were somewhat few-
er in the 6 month NAS arm (n = 10) than in the 3 month NAS
(n = 14) and RT alone arms (n = 13). The PSADTs associated with
metastases occurring in this period provide no suggestion that
any treatment related reductions in PSADT persisted beyond ﬁve
years (Table 1).
From 7.5 years onwards the interval hazards data (Fig. 1) sug-
gest the presence of a second (late) ‘‘wave’’ of DPs as described by
Morgan et al. [10], in the radiotherapy only and 3 month NAS
arms. Although the number of DPs in this ‘‘late wave’’ was small
(n = 19) a greater number were seen in men treated by RT alone
(n = 12) than by 3 month NAS (n = 6). Table 2 suggests some
interesting differences between the earlier (<7.5 years) and the
late wave of DPs. Tumours giving rise to the second wave of
DPs were of lower T stage (<0001) and Gleason score (p = 003),
and had longer times to PSA progression (p < 0001), and PSADTs
(p < 0001). Bony metastases were less frequent in this group
(p = 0006). In 10 of these 19 subjects, PSADTs became much more
rapid in the months prior to the diagnosis of metastases and 3
had puzzling periods of PSA stability at levels of 10 ng/mL or
more during their PSA rises (Figs. S3 and S4 in the electronic sup-
plement). However caution needs to be exercised in interpreting
Table 1
Distribution of PSA doubling times by trial arm according to time to distant progression from randomisation.
PSADT (mths)a Time to distant progression from randomisation (years)
<2 2–4 4–5 5–7.5 >7.5 Total
RT alone
<3 10 (16.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 10 (16.1%)
3–4 3 (4.8%) 1 (1.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (6.5%)
4–6 5 (8.1%) 5 (8.1%) 3 (4.8%) 0 (0.0%) 1 (1.6%) 14 (22.6%)
6–9 2 (3.2%) 9 (14.5%) 1 (1.6%) 3 (4.8%) 0 (0.0%) 15 (24.2%)
9–12 0 (0.0%) 0 (0.0%) 0 (0.0%) 4 (6.5%) 1 (1.6%) 5 (8.1%)
>12 1 (1.6%) 1 (1.6%) 2 (3.2%) 0 (0.0%) 10 (16.1%) 14 (22.6%)
Total 21 (33.9%) 16 (25.8%) 6 (9.7%) 7 (11.3%) 12 (19.4%) 62 (100.0%)
3 month NAS
<3 16 (26.7%) 5 (8.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 21 (35.0%)
3–4 3 (5.0%) 4 (6.7%) 0 (0.0%) 1 (1.7%) 0 (0.0%) 8 (13.3%)
4–6 2 (3.3%) 5 (8.3%) 3 (5.0%) 0 (0.0%) 0 (0.0%) 10 (16.7%)
6–9 1 (1.7%) 4 (6.7%) 4 (6.7%) 3 (5.0%) 1 (1.7%) 13 (21.7%)
9–12 0 (0.0%) 0 (0.0%) 0 (0.0%) 2 (3.3%) 2 (3.3%) 4 (6.7%)
>12 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.7%) 3 (5.0%) 14 (6.7%)
Total 22 (36.7%) 18 (30.0%) 7 (11.7%) 7 (11.7%) 6 (10.0%) 60 (100.0%)
6 month NAS
<3 8 (23.5%) 3 (8.8%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 11 (32.4%)
3–4 0 (0.0%) 3 (8.8%) 0 (0.0%) 1 (2.9%) 0 (0.0%) 4 (11.8%)
4–6 0 (0.0%) 7 (20.6%) 1 (2.9%) 1 (2.9%) 0 (0.0%) 9 (26.5%)
6–9 0 (0.0%) 2 (5.9%) 0 (0.0%) 1 (2.9%) 0 (0.0%) 3 (8.8%)
9–12 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (8.8%) 1 (2.9%) 4 (11.8%)
>12 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (8.8%) 0 (0.0%) 3 (8.8%)
Total 8 (36.7%) 15 (44.1%) 7 (11.7%) 9 (26.5%) 1 (2.9%) 34 (100.0%)
Abbreviations: PSA, prostate-speciﬁc antigen; PSADT, PSA doubling time; RT, radiotherapy; NAS, neo-adjuvant androgen suppression therapy.
a PSA doubling times in subjects diagnosed with distant progressions (DPs) prior to secondary therapeutic intervention according to the timing of DP in the three trial arms.
In 4 subjects DPs were diagnosed in the absence of PSA progression. PSADT could not be estimated in another subject.
Table 2
Distribution of primary tumour characteristics according to the timing of distant progression.
Primary tumour characteristics Distant progression within 7.5 years of
treatmentd(n = 142)
Second wave of distant progressione
(n = 19)
p Value
Gleason score 2–6 32 (22.5%) 7 (36.8%) 0.03a
7 69 (48.6%) 10 (52.6%)
8–10 41 (28.9%) 2 (10.5%)
T stage 2b 18 (12.7%) 8 (42.1%) <0.001a
2c 42 (29.6%) 7 (36.8%)
3,4 82 (57.7%) 4 (21.1%)
Pre-treatment PSA (ng/mL) <10 30 (21.1%) 6 (31.6%) 0.05a
10–19.9 38 (26.8%) 7 (36.8%)
P20 74 (52.1%) 6 (31.6%)
PSA progression kinetics (median) Time to progression (years) 1.5 5.7 <0.001b
PSA doubling time (months) 4.8 15.6 <0.001b
Sites of clinical progression Local 48 (33.8%) 6 (31.6%) 0.85c
Nodal 50 (35.2%) 10 (52.6%) 0.14c
Bony 122 (85.9%) 11 (57.9%) 0.006c
Abbreviations: PSA, Prostate-speciﬁc antigen.
a Trend test (one-tailed).
b Wilcoxon rank sum test.
c Pearson’s chi-square test (two-tailed).
d Distant progression occurs less than 7.5 years after randomisation.
e Second wave of distant progression 7.5 years or later after randomisation.
126 Metastatic processes in prostate cancerthis ‘‘second wave’’ of DPs as a single metastatic phenomenon. Six
of the 19 subjects had LPs diagnosed between 0 and 4.6 years
prior to their DPs. Their tumours tended to have lower Gleason
scores and T stage than the remaining 13 subjects without diag-
nosed LP. These six subjects also tended to have shorter PSADTs
and experienced progression in lymph nodes more frequently
than bone. However there were no trial arm related differences
between these two small subgroups. Twelve of the 19 ‘‘late wave’’
DPs occurred in the RT only arm, 6 in the 3 month NAS arm and
only 1 in the 6 month NAS arm. These DPs could therefore have
arisen prior to treatment or from recurrent primary tumours
(see electronic supplement). If the former is true then some ofthese metastatic deposits may have spent time in a dormant
state. This is certainly possible in up to 6 subjects where PSA lev-
els stabilised for periods of between 1.8 and 5.5 years before and
during their PSA ascents.Distant progressions diagnosed after STI or remaining undiagnosed
DPs were diagnosed after STI in 65 subjects. Thirty one of these
had LP before STI and 34 had PSA progressions alone. The interval
between local and PSA progression only and DP was approximately
4.5 years longer in those having STI soon after progression was
diagnosed than in those in whom STI was delayed until after DP.
J.W. Denham et al. / Radiotherapy and Oncology 107 (2013) 123–128 127As discussed in the electronic supplement, the origin of the
metastatic process in these two groups of subjects is not an easy
determination. Nevertheless minimum, maximum and reasonable
likelihood estimates for the proportions of DPs that arose from
LPs and sub-clinical metastases have been derived for subjects
treated by radiation alone as at trial closeout in electronic supple-
ment. The minimum estimate for sub-clinical metastases in this
group of 98 subjects is 41.8%, the maximum is 61.2% and a ‘‘reason-
able’’ estimate is 52%. The corresponding estimates for LP induced
DPs are 38.8%, 58.2% and 48%.
The number of subjects with DPs that were not diagnosed is
also estimated in the electronic supplement. The minimum and
maximum likelihood estimates are 37 and 122 subjects (i.e.
14.1–34.9% of all DPs).Discussion
The DP time-course data in this study suggest that approxi-
mately 52% (42–61%) of DPs in men with locally advanced, but
non-metastatic prostate cancers who have received 66 Gy alone
to the prostate arose from sub-clinical metastases present at diag-
nosis. The remaining DPs originated from viable foci of cancer in
the prostate that remained after 66 Gy. The study indicates that
3 month NAS was less effective in preventing DPs than 6 month
NAS largely because it failed to prevent the progression of sub-clin-
ical metastatic deposits present prior to treatment that were des-
tined to be diagnosed as DPs within the ﬁrst 7.5 years of follow-
up. During these years DPs were diagnosed just as frequently in
the 3 month NAS trial arm (n = 54) as in the RT alone arm
(n = 52), but almost 1.5 times more frequently than in the 6 month
NAS arm (n = 36). However 3 month NAS was more successful in
preventing DPs diagnosed 7.5 years or more after randomisation.
When compared to the RT alone arm, in which 12 DPs were diag-
nosed, DPs were reduced to 6 in the 3 month NAS arm and 1 in the
6 month NAS arm. It is probable that 3 month NAS achieved this
reduction by preventing local progression, which it did almost as
efﬁciently as 6 month NAS. This suggestion is highly compatible
with the theory advanced by Morgan et al. [10] that this belated
surge in DPs, which they dubbed the ‘‘late wave’’ of metastases
originated from LPs. However the possibility that some late
appearing DPs in all three trial arms could have evolved from
sub-clinical deposits present already at diagnosis cannot be ruled
out.
The implications of these ﬁndings for routine clinical practice
are twofold. For men with ‘‘high-risk’’ localised prostate cancers,
(where sub-clinical metastatic deposits are likely to be present at
diagnosis in P20%), adjuvant AS will remain necessary because
radiation dose escalation will not prevent these metastatic depos-
its from progressing. However in men at lower risk of sub-clinical
metastases the need for adjuvant AS is much more limited and in
low-risk patients radiation dose escalation is likely to prevent the
majority of DPs. However, our time-course data suggest that this
approach is unlikely to cause signiﬁcant reductions in prostate
cancer speciﬁc mortality until 15 years of follow-up has been
undertaken.
Our report is not the ﬁrst to document more rapid PSADTs in
men receiving NAS. Shorter PSADTs have been reported in PSA pro-
gressions following 3 month NAS in radiotherapy and surgical ser-
ies [11–13]. So far as we are aware however, no attempts have
been made to determine whether the phenomenon is related to
an acceleration of the metastatic process. Because PSADTs associ-
ated with DPs were signiﬁcantly more rapid in the 3 month NAS
arm than in the RT alone arm (Table 1) we feel it is reasonable to
accept the possibility that testosterone recovery following 3 month
NAS has induced more rapid PSADT in surviving sub-clinical met-astatic deposits. However our DP time-course data (Figs. 1 and 2)
are more compatible with delays in the progression of sub-clinical
metastases due to androgen suppression itself than to accelerated
progressions from testosterone recovery. In the 6 month NAS arm a
relative reduction in short PSADTs was observed. However, be-
cause there was no increase in short PSADT DPs compared to the
RT alone arm we feel the data are more compatible with the pre-
vention of a large number of DPs with PSADT >3 months by
6 month NAS (Table 1) than a genuine induction of short PSADTs
in surviving sub-clinical deposits. Fortunately the clinical implica-
tions of the acceleration in PSADT seen in subjects receiving
3 month NAS in this study is likely to be limited if conﬁrmed in
prospective studies. Although 3 month NAS remains a commonly
used neo-adjuvant regimen in many countries, most men with
high risk localised cancers already receive more prolonged courses
of AS due to the varying beneﬁts demonstrated by large scale trials
[14–17].
Five limitations of this study need to be highlighted. The ﬁrst is
that only 161 DPs were diagnosed prior to STI and 65 afterwards.
This limited the power of the study to recognise treatment arm re-
lated differences in both the time-courses of DP and associated
PSADTs. The second is that DPs could have occurred more fre-
quently and earlier than described for two reasons: Firstly due to
competing risks such as inﬁrmity, loss to follow-up and death
occurring prior to diagnosis and secondly, due to the less sensitive
imaging technology in use. Our likelihood estimates indicated that
the proportion of subjects who had ‘‘missed’’ or yet to be diagnosed
DPs was between 14% and 35% sometime after 7.5 years. The third
limitation related to our LP data. Unfortunately local progression is
difﬁcult to diagnose reliably by digital examination and the magni-
tude of the reductions found is open to doubt. In RTOG 94.06 and
two Canadian randomised controlled trials where prostatic biop-
sies were planned to occur 24 months after radiation, persistent
cancer was found in as many as 65% of men treated by radiation
alone, 14–28% in men treated with 3 or 4 month NAS and 5–9%
of men treated with 8 or 9 month NAS [18–20]. Had biopsy and
MRI data been available the frequency and timing of our LP esti-
mates could have been more reliable. These, in turn, could have in-
formed better estimates of the proportions of LPs that lead directly
to subsequent DPs and ruled out dormant SCM as an explanation
for their origins. In spite of these caveats the proportion of DPs
thought to have originated from LPs would not have been seriously
underestimated because LP was not assumed to be absent in sub-
jects without LP diagnoses. The fourth is that ‘‘immortal time
biases’’ could have inﬂuenced the characterisation of subjects with
late appearing DPs [3,21]. Comparison of this group with subjects
experiencing earlier DPs therefore should be viewed cautiously.
The ﬁfth limitation of this study is the sparsity of data regarding
the characterisation and the duration of the sub-clinical growth
phase of prostate cancer metastases. Better data would have en-
abled us to interpret our results with greater precision.Conﬂict of interest statement
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